Peer Review History
| Original SubmissionFebruary 11, 2021 |
|---|
|
PONE-D-21-04729 Rotavirus susceptibility of antibiotic-treated mice ascribed to diminished expression of interleukin-22 PLOS ONE Dear Dr. Staeheli, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised by three experts who reviewed your study. Please submit your revised manuscript by May 02 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Michael Nevels Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: No Reviewer #2: Yes Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This work presents data that indicates that C57BL/6 mice are highly, if not completely resistant to infection by WT murine rotavirus and that this resistance can be alleviated by ablation of microbiota by either antibiotics or germfree approaches. They then go on to show that such treatments reduce IL-22 and that exogenous IL-22 protects against rotavirus, and that all of these findings are independent of type 1 IFN. There is not really all that much new here but, nonetheless, the work cold revised to make a reasonable contribution to the literature but major revisions in how they present and interpret their findings are needed. Infection of C57BL/6 mice with murine rotavirus EC strain is a very widely used model of rotavirus infection, used for many years. Accordingly, when such mice are directly purchased from most commercial vendors and bred at many institutions, they will display clear shedding of RV antigens and genomes. Here, the authors report that such mice bred at 2 different institutions were not infectable by RV unless first exposed to antibiotics. I don’t doubt the observation they made but how they present it and interpret it is highly problematic. Firstly, they don’t actually acknowledge that the untreated mice were not, in fact, infected with RV at all and thus that they their positive control did not work as it has in the literature for over 20 years. Consequently, they have not really interpreted and properly contextualized the antibiotic data. The proper interpretation is that, for some reason, their mice are highly RV resistant, relative to mice long used in the literature which can be readily infected by this RV strain. They mention “timing of virus excretion” as a possible explanation but I have no idea what they mean by this. Countless studies have shown adult C57BL/6 shed mice within a few days of inoculation and their assay period certainly covers this time. It is certainly appropriate to cite reference 19 to speculate that the mice studied here might also be RV-resistant to their specific microbiota composition but again they need to start by acknowledging that their mice contradict the well-established phenotype. Moreover, this makes it very difficult to compare their findings with published papers that started with the typical readily-infectable mice and then examined impacts of antibiotics and germfree conditions. Reviewer #2: Dear Authors, It is a very important scientific work and would definitely contribute in the advancement of the current knowledge about the influence of microbiome and its corelation with antibiotics on viral infections. I would strongly suggest you the improvement of all figures. I am unable to clearly read what is written along x axis and y axis. Kindly improve it. It is in bold letters, it will be more convenient for the readers if it appears in normal letters. Moreover at line number 142 (Antibiotic treatment of Mice), kindly mention the mode of adminstration of antibiotics, as I could not get it completely. you are requested to make it clear weather the antibiotics were adminsitered orally or intramuscular or intravenous. The rest is fine to my understanding. Reviewer #3: The manuscript titled “Rotavirus susceptibility of antibiotic-treated mice ascribed to diminished expression of IL-22” by Schnepf et al describes the finding that rotavirus, a common intestinal viral infection, replicates more efficiently in the intestines of germ free and antibiotic treated mice compared to wild type mice. The authors ascribe this finding to the fact that the microbiome is altered in the germ free and antibiotic treated mice. The effect was associated with the diminished expression of IL-22 and when IL-22 was administered to germ free mice, the replication of the virus was blocked presenting with a more wild type phenotype. They present several experiments that exclude specific pathways that could explain this finding including interferon, glycosylation patterns, necroptosis, and pyroptosis. Although the findings are interesting and provocative, the authors do not provide an explanation for their findings beyond the association with IL22. There is a vast volume of literature in the murine model of rotavirus over the last 35 years and a recent publication from Shi et al (Cell 2019) that directly contradict what is presented here. This descriptive observation, which lacks full development and explanation, adds little to the scientific field. In addition, discrepancies in the experimental approach raises some concerns. Major Concerns: This paper needs several crucial modifications before it can be published. Overall, the introduction needs to be more informative about rotavirus-specific interactions with bacteria and IL-22. The presented results are strong and the discovery that IL-22 is dependent on gut microbiota is excellent but more information is needed about the strain of rotavirus used for each experiment and more discussion is needed about variation in susceptibility of replicate mice. The discussion largely repeats the results and should instead be put into context with the other viral interactions currently in the discussion. Although the mechanism remains elusive, the authors do not postulate a possible pathway based on literature detailing what is known about the interplay between bacteria and immune effectors. 1. This paper directly contradicts over 35 years of work in the murine model by at least 5 major research groups and many more smaller groups. Recently, it was published that antibiotic treatment reduced rather than promoted rotavirus infection (Shi et al Cell 2019). Although the authors do acknowledge this publication, a more depth discussion is necessary to provide explanation beyond IL22 as to why these data differ from the vast volume of previous studies. 2. The gnotobiotic piglet models (Yuan et all JV 1998) has been used for many years and does not seem to model the authors findings here. Discussing the findings in the context of these published results is warranted and should be included in the discussion. 3. Lines 238-286: Although the authors are looking at the immune effectors that contribute to this resistance rather than specific microbiome composition, and they reference Shi et all Cell 2019, the authors do not test for the presence of SFB. Thus it is not clear whether this work is extending the findings of Shi et al or the authors have found a completely independent protective mechanism from RV. The mice should be tested for the presence of SFB either through SFB-specific qPCR or another 16S sequencing approach. More evidence that this extends the work of Shi et al is needed before publication. Rewording the introduction and the discussion is recommended as well as adding qPCR specific for SFB. 4. There are major differences in virulence between the EDIM strain and the EC strain. An explanation should be included in the discussion as to the differences in virulence of these strains and how it might affect the interpretation of the results. Line 239 and 248: Since authors are using 2 different strains of rotavirus, they should specify which strain they are referring to (EDIM or EC). Also reference strain in the figure legends 5. Microarray is an outdated method in which to assess transcriptional changes. State of the art approaches should utilize RNAseq based transcriptomics 6. Since viral stocks were made from intestinal and fecal isolates that were rich in microbial organisms, some description is necessary as to how the authors ensured that the inoculum was bacteria free. 7. Immunofluorescence for RV antigen in intestinal sections should be included to demonstrate there is no infection in the wild type animals. Minor Concerns: 1. With antibiotics in the drinking water, how was the amount of antibiotic that each animal received controlled for and how would this affect the microbiome differently in each animal. This could perhaps explain the large differences in the shedding curves of each animal. 2. 16S sequencing should be done before and after antibiotic treatment in order to verify that large changes in the microbiome were occurring with treatment. The different mouse strains used may not have comparable microbiomes 3. Rotavirus is a small intestinal infection and so it is not clear why colonic samples were used for the viral stock of EDIM rather than small intestine. An explanation should be included in the materials and methods. 4. An upaired student’s t test does not seem the appropriate test to assess statistical significance. Studies using this statistical test should have more than six samples in each group and with this data, the ability to generalize to a larger population is difficult. Appropriate statistical tests should be performed. 5. It is not clear whether all the animals were on the same food and water. This would be important as it could explain some of the differences the authors observed. The description of food and water should be included in the materials and methods. 6. Were the animals prechecked for the presence of serum RV antibodies that might suggest the animals had previously seen RV? This should be done and stated in the materials and methods. 7. Line 291 Why were IFNLR1-/- mice used instead of WT mice for these studies. More rationale should be included. 8. In Figure 3 A and B why is there such a large difference in expression levels in the SPF controls. A discussion of this should be included in the results. 9. Figures 3 C and D need complete shedding curves and area under the curve calculated as performed in O’Neal et all Virology 1997. 10. In Figure 2, day 5 seems too late to assess viral shedding based on the work of Offit, Greenberg, Ward, Estes, Connor. Earlier timepoints should be presented. 11. What does the statement in lines 325-326 mean about the timing? The timing of shedding of rotavirus in the murine model of rotavirus infection has been well documented over the last 30 years by multiple groups (Offit, Greenberg, Ward, Estes, Connor) 12. Line 94-98: The authors should mention that IL-22 is known to be protective from rotavirus infection (reference 18) 13. Line 242 and 249: Loss of infectivity in C57BL6 adult mice is highly surprising. The SFB protection from RV reported by Shi et al was the first identification of a resistant mouse model. A short statement such as “this was surprising given reports of consistent infection in previous studies” should be added to put the discovery in context for readers. 14. Line 249 and Figure 2: The authors should make it clear whether the baseline of 3e10 genome copies per fecal pellet is the limit of detection or the expected amount of RV shedding. It is unclear whether the mice at the second independent institution were also resistant to RV infection or simply had an increase from baseline infectivity. 15. Line 255-256 and Figure 2: No reference is made to the variability in the -Abx condition, despite the fact that this hints at variation either in the microbiota composition or the IL-22 signaling. Some discussion on this point should be included. Comparison between mice that are highly susceptible and those that are less susceptible may even be helpful in determining the mechanism. 16. Line 265-266: It should be clarified that these are basal levels in the absence of infection 17. Line 295-304: As Fut2 enables RV entry, it is not clear why an increase in Fut2 would confer resistance to RV infection. More rationale should be included to understand the logic behind this statement. 18. Line 315 and Figure 5B: The authors do not discuss why there is reduced shedding in saline treated Casp1/11-/- Abx mice as compared to other mouse models treated with Abx. A discussion should be included to address this. 19. Figure 5 legend: The question mark following pyroptosis is unnecessary. 20. Lines 46 and 296: The comments about O glycosylation are incorrect. Fut 2 adds fucose moieties to glycoproteins and glycolipid so they are fucosylated glycans on the cell surface. This enzyme has nothing to do with O glycans. There are no O molecules linked to rotavirus entry. The wording should be modified ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Rotavirus susceptibility of antibiotic-treated mice ascribed to diminished expression of interleukin-22 PONE-D-21-04729R1 Dear Dr. Staeheli, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Michael Nevels Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: N/A Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: While the provide an explanation that they don't mean to declare C57BL/6 with a microbiota un-infectable by RV their data seems to do exactly that. Indeed, this could reflect a low inoculum but, given this work generally lacks novelty and is trying to reconcile some previously published work, they need to at least start with the widely used previous conditions in which C57BL6 mice purchased from standard vendors shed copious amounts of RV. Fine to then use a lower inoculum, but starting with a POSITIVE CONTROL IS ESSENTIAL. Reviewer #2: In the research article entitled Rotavirus susceptibility of antibiotic-treated mice ascribed to diminished expression of interleukin-22, the authors have incorporated all the suggested changes except the fonts of the figures that are still bold and one can not read them. It is requested to make those fonts readable. Regards Reviewer #3: The authors have substantially expanded both the introduction and discussion to put their findings in the context of the field. Additionally, they have clarified experimental details. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Nazish Bostan. Reviewer #3: No |
| Formally Accepted |
|
PONE-D-21-04729R1 Rotavirus susceptibility of antibiotic-treated mice ascribed to diminished expression of interleukin-22 Dear Dr. Staeheli: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Michael Nevels Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .